152 related articles for article (PubMed ID: 34586000)
1. NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
Alderuccio JP; Lossos IS
Leuk Lymphoma; 2022 Feb; 63(2):279-290. PubMed ID: 34586000
[TBL] [Abstract][Full Text] [Related]
2. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
Rossi D; Trifonov V; Fangazio M; Bruscaggin A; Rasi S; Spina V; Monti S; Vaisitti T; Arruga F; Famà R; Ciardullo C; Greco M; Cresta S; Piranda D; Holmes A; Fabbri G; Messina M; Rinaldi A; Wang J; Agostinelli C; Piccaluga PP; Lucioni M; Tabbò F; Serra R; Franceschetti S; Deambrogi C; Daniele G; Gattei V; Marasca R; Facchetti F; Arcaini L; Inghirami G; Bertoni F; Pileri SA; Deaglio S; Foà R; Dalla-Favera R; Pasqualucci L; Rabadan R; Gaidano G
J Exp Med; 2012 Aug; 209(9):1537-51. PubMed ID: 22891273
[TBL] [Abstract][Full Text] [Related]
3. Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.
Righi S; Novero D; Godio L; Bertuzzi C; Bacci F; Agostinelli C; Sagramoso C; Rossi M; Piccioli M; Gazzola A; Mannu C; Roncador G; Sabattini E
Hum Pathol; 2022 Jun; 124():67-75. PubMed ID: 35339566
[TBL] [Abstract][Full Text] [Related]
4. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of splenic and nodal marginal zone lymphoma.
Spina V; Rossi D
Best Pract Res Clin Haematol; 2017; 30(1-2):5-12. PubMed ID: 28288716
[TBL] [Abstract][Full Text] [Related]
6. Splenic marginal zone lymphoma: current knowledge and future directions.
Thieblemont C; Davi F; Noguera ME; Brière J; Bertoni F; Zucca E; Traverse-Glehen A; Felman P; Berger F; Salles G; Coiffier B
Oncology (Williston Park); 2012 Feb; 26(2):194-202. PubMed ID: 22489356
[TBL] [Abstract][Full Text] [Related]
7. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
8. Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.
Shanmugam V; Craig JW; Hilton LK; Nguyen MH; Rushton CK; Fahimdanesh K; Lovitch S; Ferland B; Scott DW; Aster JC
Blood Adv; 2021 Jan; 5(1):71-83. PubMed ID: 33570635
[TBL] [Abstract][Full Text] [Related]
9. Splenic marginal zone lymphoma with monoclonal IgG: A case report.
Zhang X; Ren S; Zhang N; Wang X; Qiu L; Sun H; Yi H; Fan F
Medicine (Baltimore); 2024 Feb; 103(6):e37158. PubMed ID: 38335376
[TBL] [Abstract][Full Text] [Related]
10. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
11. Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.
Sbattella M; Zanichelli A; Ghia P; Gattei V; Suffritti C; Teatini T; Cicardi M; Castelli R
Med Oncol; 2018 Aug; 35(9):118. PubMed ID: 30073422
[TBL] [Abstract][Full Text] [Related]
12. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.
Clipson A; Wang M; de Leval L; Ashton-Key M; Wotherspoon A; Vassiliou G; Bolli N; Grove C; Moody S; Escudero-Ibarz L; Gundem G; Brugger K; Xue X; Mi E; Bench A; Scott M; Liu H; Follows G; Robles EF; Martinez-Climent JA; Oscier D; Watkins AJ; Du MQ
Leukemia; 2015 May; 29(5):1177-85. PubMed ID: 25428260
[TBL] [Abstract][Full Text] [Related]
13. Role of Notch2 pathway in mature B cell malignancies.
Mesini N; Fiorcari S; Atene CG; Maffei R; Potenza L; Luppi M; Marasca R
Front Oncol; 2022; 12():1073672. PubMed ID: 36686759
[TBL] [Abstract][Full Text] [Related]
14. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
Bastidas-Mora G; Beà S; Navarro A; Gine E; Costa D; Delgado J; Baumann T; Magnano L; Rivas-Delgado A; Villamor N; Colomer D; Lopez-Guerra M; Rozman M; Balagué O; Martínez D; Baptista MJ; Escoda L; Alcoceba M; Blanes M; Climent F; Campo E; Wotherspoon A; López-Guillermo A; Matutes E
Br J Haematol; 2022 Jan; 196(1):146-155. PubMed ID: 34519021
[TBL] [Abstract][Full Text] [Related]
15. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
Wu L; Tian C; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.
Kiel MJ; Velusamy T; Betz BL; Zhao L; Weigelin HG; Chiang MY; Huebner-Chan DR; Bailey NG; Yang DT; Bhagat G; Miranda RN; Bahler DW; Medeiros LJ; Lim MS; Elenitoba-Johnson KS
J Exp Med; 2012 Aug; 209(9):1553-65. PubMed ID: 22891276
[TBL] [Abstract][Full Text] [Related]
17. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
18. Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis.
Cagliuso M; Conti V; Trasarti S; Lombardi L; Riminucci M; Perez M; Turriziani O; Falasca F; Nanni M; Tafuri A; Mezzaroma I
Infection; 2013 Feb; 41(1):255-8. PubMed ID: 23007326
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
Gailllard B; Cornillet-Lefebvre P; Le QH; Maloum K; Pannetier M; Lecoq-Lafon C; Grange B; Jondreville L; Michaux L; Nadal N; Ittel A; Luquet I; Struski S; Lefebvre C; Gaillard JB; Lafage-Pochitaloff M; Balducci E; Penther D; Barin C; Collonge-Rame MA; Jimenez-Poquet M; Richebourg S; Lemaire P; Defasque S; Radford-Weiss I; Bidet A; Susin SA; Nguyen-Khac F; Chapiro E;
Br J Haematol; 2021 Apr; 193(1):72-82. PubMed ID: 33314017
[TBL] [Abstract][Full Text] [Related]
20. Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Muntañola A; Villalobos MT; González-Villambrosia S; Rodríguez-Salazar MJ; Jiménez-Ubieto A; Bastidas-Mora G; Córdoba R; Infante M; Vidal MJ; Díaz FJ; Baile M; Bastos-Oreiro M; Panizo C; Sancho JM; Navarro B; García T; Escoda L; Abrisqueta P; Terol MJ; de Campo R; Mozas P; López-Guillermo A; Salar A; Montalbán C;
Br J Haematol; 2023 Aug; 202(4):776-784. PubMed ID: 37386877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
